Adverum Biotechnologies, Inc.
شراء
تم تحديثه

ADVM reiteration

197
With the recent advancements about the possible change of board members and the earnings report, finally ADVM should start its climb. The first target is $3.80.
ملاحظة
Decrease in the short volume ratio on the stock is also a positive sign. Despite a penny increment sell wall, we are expecting the climb to resume.
ملاحظة
It is making its comeback. With the institutional support for the success of the company, my target price is $5.60 in the short to middle term. As soon as the issues with the Phase 2 incidence is discovered, the price will slowly regain its valued range of $15-$20.

إخلاء المسؤولية

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.